"The U.S. Food and Drug Administration today allowed marketing of the Eclipse System for the treatment of fecal incontinence (FI) in adult women.
Fecal incontinence is the inability to control bowel movements and is a common problem, espec"...
The natural digestive enzymes in VIOKASE® (pancrelipase tablets, powder) hydrolyze fats into fatty acids and glycerol, split protein into amino acids, and convert carbohydrates to dextrins and short chain sugars.
Under conditions of the USP test method (in vitro) VIOKASE® (pancrelipase tablets, powder) has the following total digestive capacity:
| VIOKASE® Powder
Each 0.7 g (1/4 Teaspoonful)
|Dietary fat, grams||28||56||59|
|Dietary protein, grams||30||60||70|
|Dietary starch, grams||30||60||70|
VIOKASE® (pancrelipase tablets, powder) 8 Tablets are 468 mg immediate release tablets and are not enteric-coated. VIOKASE® (pancrelipase tablets, powder) 16 Tablets are 935 mg immediate release tablets and are not enteric-coated.
Last reviewed on RxList: 12/9/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Viokase Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.